Oxycodone/paracetamol controlled release - Mallinckrodt

Drug Profile

Oxycodone/paracetamol controlled release - Mallinckrodt

Alternative Names: Acetaminophen/oxycodone hydrochloride; COV-795; MNK-795; Oxycodone hydrochloride/acetaminophen; Xartemis XR

Latest Information Update: 29 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mallinckrodt Inc.
  • Class Acetanilides; Antipyretics; Antirheumatics; Morphine derivatives; Non-opioid analgesics; Opioid analgesics
  • Mechanism of Action Opioid delta receptor agonists; Opioid kappa receptor agonists; Opioid mu receptor agonists; Prostaglandin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Acute pain

Most Recent Events

  • 22 Nov 2016 Phase-I clinical trials in Acute pain (In volunteers) in USA (PO) (NCT02966860)
  • 15 Nov 2016 Mallinckrodt completes the phase I trial in Healthy volunteers in USA (NCT02966860)
  • 17 Apr 2014 Launched for Acute pain in USA (PO) - First global launch
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top